CellMosaic to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

11th Apr 2018

Woburn, MA, April 11, 2018 – CellMosaic is going to present our work on developing water soluble AqueaTether™ (AqT™) carriers for Drug Conjugation and Delivery at the upcoming AACR meeting at McCormick Place in Chicago, Illinois. Please come and visit us during the poster session. We are currently looking for partners who can further develop and utilize the AqT™ program.

Session Category (Title): Antibody–Drug Conjugates: Agents and Technology

Date: Sunday 4/15/2018

Session Time: 1:00 - 5:00 PM (CDT)

Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 22

Poster Number: 755

Poster Title: Synthesis and Evaluation of Sugar Alcohol Based Molecules for Drug Conjugation and Delivery

About CellMosaic, Inc.

CellMosaic, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. Several key technologies are being developed at CellMosaic, including oxLink technologies for studying protein–protein interactions; NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest; super-hydrophilic AqueaTether linkers for clean conjugation of antibody/protein/peptide/oligo with small molecule drugs; biocompatible, biodegradable, mono-dispersed AqueaTether macromolecules for modification of protein/peptide/oligo drugs and preparation of highly loaded small molecule drugs for better delivery; and bioconjugation platform technologies involving screening, labeling/crosslinking, purification, and analysis of any bioconjugate. The company is also actively engaged in serving biological communities by providing custom synthesis of high quality bioconjugate products.

About AqueaTether Therapeutics.

AqueaTether Therapeutics is a division of CellMosaic, created in 2016. AqueaTether™ Therapeutics focuses on the discovery and development of novel hybrid drug entities beyond the conventional drug classes by using AqueaTether ™ (AqT™) conjugation and delivery platform technologies. We work together with our partners to advance their program. For more information regarding AqueaTether-based bioconjugate drugs, please visit our website: www.aqttherapeutics.com